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Abstract
Objective:  the  low  degree  of  inﬂammation  in  obesity  contributes  to  systemic  metabolic  dys-
function. Recent  experimental  studies  proposed  some  effects  of  alteration  in  gut  microbiota  on
inﬂammatory  factors.  This  study  aimed  to  assess  the  anti-inﬂammatory  effects  of  a  synbiotic
supplement  on  inﬂammation  markers  in  overweight  and  obese  children  and  adolescents.
Methods: this  randomized  triple-masked  controlled  trial  was  conducted  among  70  participants
aged 6  to  18  years,  with  a  body  mass  index  (BMI)  equal  or  higher  than  the  85th  percentile.  They
were  randomly  assigned  into  two  groups  of  equal  number  to  receive  synbiotic  or  placebo  for
eight  weeks.
Results:  ﬁfty-six  of  70  participants  (80%)  completed  the  study.  Compared  with  the  placebo
group, the  synbiotic  group  had  signiﬁcant  decrease  in  mean  values  of  tumor  necrosis-  and
interleukin-6,  with  signiﬁcant  increase  in  adiponectin;  these  changes  were  no  longer  signiﬁcant
after  adjustment  for  BMI.  There  was  no  signiﬁcant  change  in  the  mean  values  of  high-sensitive
C-reactive  protein.
Conclusion:  the  present  ﬁndings  suggest  the  positive  inﬂuence  of  synbiotic  supplementation  on
inﬂammation  factors,  which  are  dependent  to  its  effect  on  weight  reduction  in  overweight  and
obese  children.
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Ensaio  clínico  controlado  randomizado  triplo-cego  dos  efeitos  de  simbióticos  sobre
marcadores  de  inﬂamac¸ão  em  crianc¸as  com  sobrepeso
Resumo
Objetivo:  o  baixo  grau  de  inﬂamac¸ão  na  obesidade  contribui  para  disfunc¸ão  metabólica
sistêmica. Estudos  experimentais  recentes  propuseram  alguns  efeitos  de  alterac¸ão  na  micro-
biota  intestinal  sobre  fatores  inﬂamatórios.  O  objetivo  deste  estudo  foi  avaliar  os  efeitos
anti-inﬂamatórios  de  um  suplemento  simbiótico  sobre  marcadores  de  inﬂamac¸ão  em  crianc¸as
e adolescentes  com  sobrepeso  e  obesos.
Métodos:  este  ensaio  clínico  controlado  randomizado  triplo-cego  foi  conduzido  entre  70  partic-
ipantes  com  idade  entre  seis  e  18  anos,  com  índice  de  massa  corporal  (IMC)  igual  ou  acima  do  85◦
percentil.  Eles  foram  aleatoriamente  divididos  em  dois  grupos  de  igual  número  de  participantes
para  receber  simbiótico  ou  placebo  por  oito  semanas.
Resultados:  no  todo,  56  de  70  participantes  (80%)  concluíram  o  estudo.  Em  comparac¸ão  ao
grupo placebo,  o  grupo  simbiótico  teve  reduc¸ão  signiﬁcativa  nos  valores  médios  de  necrose
tumoral-  e  interleucina-6,  com  aumento  signiﬁcativo  na  adiponectina;  essas  alterac¸ões  não
eram  mais  expressivas  após  o  ajuste  do  IMC.  Não  houve  alterac¸ão  importante  nos  valores  médios
da  proteína  C-reativa  altamente  sensível.
Conclusão:  nossas  conclusões  sugerem  a  inﬂuência  positiva  da  suplementac¸ão  simbiótica  sobre
fatores  inﬂamatórios,  dependente  de  seu  efeito  sobre  a  reduc¸ão  de  peso  em  crianc¸as  com
sobrepeso  e  obesas.
© 2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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he  emerging  global  epidemic  of  obesity  is  a  serious  health
roblem at  individual  and  public  health  levels.  This  is  of
pecial concern  for  the  pediatric  age  group.  Obesity  is
ssociated with  chronic  low-grade  inﬂammation,  which  con-
ributes to  the  systemic  metabolic  dysfunction  linked  to
besity-linked disorders,  such  as  metabolic  syndrome.1
Increased  expression  and  production  of  cytokines  and
cute phase  reactants  such  as  C-reactive  protein  (CRP),
nterleukins (ILs),  tumor  necrosis  factor    (TNF-  ),  or
ipopolysaccharides (LPS)  result  in  the  low  degree  of  inﬂam-
ation among  obese  individuals.2,3
Some  studies  proposed  that  gut  microbiota  may  partic-
pate in  the  whole-body  metabolism  by  affecting  energy
alance, glucose  metabolism,  and  low-grade  inﬂammation
ssociated with  obesity  and  related  metabolic  disorders.4
It  is  documented  that  gut  microbiota  are  different  among
bese and  eutrophic  individuals.5,6 Gut  microbiota-derived
PS are  known  as  a  factor  involved  in  the  onset  and  pro-
ression of  inﬂammation  and  metabolic  disorders.7 LPS  are
 component  of  Gram-negative  bacteria  cell  walls,  which
re among  the  most  potent  and  well-studied  inducers  of
nﬂammation. 4
Moreover,  any  change  in  the  gut  microbiota  may  lead  to
hange in  the  production  of  endotoxin  and  thus  change  in
he LPS  levels.7,8
Although  the  intestinal  epithelium  acts  as  a  continuous
arrier to  avoid  LPS  translocation,  some  events  can  dam-
ge this  barrier.  For  instance,  a  study  demonstrated  that
he modulation  of  gut  bacteria  following  a  high-fat  diet
trongly increased  the  intestinal  permeability  by  reducing
he expression  of  genes  coding.9
Therefore,  it  can  be  assumed  that  regulating  gut  micro-
Eiota may  be  an  appropriate  strategy  to  control  obesity  and
ts related  disorders.
a
dTherefore,  it  was  hypothesized  that  supplementation
ith synbiotics,  which  modulates  gut  microbiota  and  their
roduction, may  be  effective  in  changing  markers  of  inﬂam-
ation in  individuals  with  excess  weight.  This  study  aimed
o investigate  the  effect  of  synbiotic  supplementation  on
nﬂammatory factors  in  overweight  and  obese  children  and
dolescents.
ethod
he  detailed  methods  of  this  study  have  been  previously
ublished;10 the  ﬁndings  on  markers  of  inﬂammation,  which
ave not  been  reported  before,  are  presented  here.  The
tudy was  conducted  from  September  to  November  of  2011
t the  Isfahan  University  of  Medical  Sciences  (IUMS),  Isfahan,
ran. It  was  a  randomized  triple-blinded  controlled  trial,  i.e.
he researchers,  participants  and  statistician  were  masked
o the  groups  under  study.
The  trial  protocol  was  in  accordance  with  the  Declaration
f Helsinki,  and  was  approved  by  the  Research  and  Ethics
ommittee of  IUMS.  The  trial  was  registered  under  trial  reg-
stry code  IRCT201103081434N4  at  the  national  registry  for
linical trials,  which  is  a  member  of  the  World  Health  Orga-
ization.
After providing  detailed  information,  an  informed  con-
ent was  signed  by  parents,  and  oral  assent  from  participants
as obtained.
articipants
0  apparently  healthy  children  and  adolescents,  aged  6  to
8 years,  with  a  body  mass  index  (BMI)  equal  to  or  higher
han the  age-  and  gender-speciﬁc  85th  revised  percentiles
um artigo Open Access sob a licença de CC BY-NC-NDre in  close  agreement  with  the  percentiles  of  Iranian  chil-
ren and  adolescents,12 were  selected  by  random  sampling
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from  children  who  were  referred  to  the  Pediatric  Obesity
and Metabolic  Syndrome  Clinic  of  the  Child  Growth  and
Development Research  Center  of  the  IUMS.  Participants  were
randomized  to  either  synbiotic  (n  =  35)  or  placebo  (n  =  35)
groups through  random  table  numbers.  Children  with  syn-
dromal obesity,  endocrine  disorders,  any  physical  disability,
history of  chronic  medication  use,  use  of  mineral  and/or
vitamin supplements,  history  of  any  chronic  diseases  and/or
chronic medication  use,  or  those  under  special  diets  were
not included  in  the  study.  The  trial  duration  was  eight  weeks,
and both  groups  received  similar  counseling  for  lifestyle
modiﬁcation regarding  dietary  and  physical  activity  habits.
Physical  examination
The  participants’  age  and  birth  date  were  recorded.  All
anthropometric measurements  were  made  by  the  same
trained person  and  under  the  supervision  of  the  same  pedia-
trician. Physical  examination  was  conducted  under  standard
protocols through  calibrated  instruments  at  the  beginning
and end  of  the  trial.
Body  weight  was  measured  with  a  digital  ﬂoor  scale  (Seca
- Hamburg,  Germany)  with  100  g  accuracy,  without  shoes  and
with minimum  clothing.  Height  was  measured,  with  1  mm
accuracy, with  a  non-stretch  tape.
Waist  and  hip  circumferences  were  measured  with  a  non-
elastic tape.  Waist  circumference  was  measured  at  a  point
midway between  the  lower  border  of  the  rib  cage  and  the
iliac crest  at  the  end  of  normal  expiration.  Hip  circumfer-
ence was  measured  at  the  maximum  girth  of  the  buttocks,
and waist-to-hip  ratio  was  calculated.
Biochemical  measurements
Participants  were  instructed  to  fast  for  12  hours  before  blood
sampling. With  one  of  the  parents  accompanying  his/her
child, blood  samples  were  taken  from  the  antecubital  vein
between 08:00  and  09:30  am.  After  collecting  blood  sam-
ples, the  participants  were  served  a  healthy  snack  provided
by the  project  team.  CRP,  TNF-,  IL-6,  and  adiponectin  were
measured enzymatically  with  standard  auto-analyzer  kits
(Pars Azmoun,  Iran).
Synbiotic  administration
Synbiotic  capsules  (Protexin  -  London,  England)  were
used, each  containing  2.0  ×  108 colony-forming  units
(CFU)/day. They  contained  a  combination  of  viable
frozen-dried)Lactobacillus  casei,  Lactobacillus  rhamnosus,
Streptococcus thermophilus,  Biﬁdobacterium  breve,  Lacto-
bacillus acidophilus,  Biﬁdobacterium  longum,  Lactobacillus
bulgaricus) of  human  origin  with  prebiotics  (frocto  oligosac-
charides), vitamin  E,  vitamin  A,  and  vitamin  C.  The  children
and adolescents  assigned  to  the  synbiotic  group  were
instructed to  take  one  capsule  a  day  before  a  main  meal
for eight  weeks.The placebo  was  prepared  in  the  Pharmaceutics  Depart-
ment of  the  Faculty  of  Pharmacy  of  the  IUMS.  It  contained
maltodextrine and  consisted  of  capsules  with  shape,  taste,
and smell  identical  to  the  synbiotic  capsules.
S
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In addition  to  regular  visits  of  participants,  medication
dherence was  tracked  by  stool  sample  collection  and  the
ount of  bacteria  in  stool,  as  well  as  by  weekly  phone  call
o participants.
tool  sample  collection
tool  samples  were  collected  from  both  synbiotic  and
lacebo groups  at  baseline  and  on  the  days  15  and  60  of
he trial.  Samples  were  kept  refrigerated  in  sealed  plastic
eces containers  for  less  than  six  hours  until  they  were  trans-
erred to  the  laboratory,  where  they  were  examined  at  the
arliest possible  time.
edia
RS  agar  (Merck  - Germany,  pH  =  5.7)  and  MRS  agar  (Merck
 Germany,  pH  =  5.7)  combined  with  1%  muprocin  (Sigma
 United  States)  and  0.5%  systein  hydrochloride  (Sigma  -
nited States)  were  used  for  enumeration  of  Lactobacillus
nd Biﬁdobacterium  colonies,  respectively.
acterial  counts
ach  fecal  sample  (0.5  g)  was  placed  in  the  sterilized  tube
ombined with  5  mL  of  sterile  normal  saline,  mixed  thor-
ughly, and  centrifuged  for  5  minutes  at  100  rpm.  1  mL  of  the
pper phase  was  serially  tenfold-diluted  to  a 10−7 dilution.
100  L  of  the  proper  dilution  was  surface-cultured  on
oth types  of  plates.  Plates  were  incubated  anaerobically
ith 5%  CO2, using  a  CO2-injected  incubator.  MRS  plates
ere kept  at  37◦ to  38 ◦C  for  48  hours,  and  the  plates  con-
aining MRS-muprocin-hydrochloride  were  kept  at  the  same
emperature for  72  hours.
Colony counting  was  performed  by  an  expert  and
xpressed as  a  log  of  the  CFU  per  gram  of  fresh  feces.
ietary  records
utrient  intakes  were  estimated  using  three-day  dietary
ecord (two  weekdays  and  one  weekend  day)  at  the  begin-
ing and  at  the  end  of  the  study.  Participants  were  asked
o write  down  the  type  and  amount  of  food  eaten,  using
cales or  household  measures  to  gauge  portion  sizes  where
ossible. Three-day  averages  of  energy  and  macronutrient
ntakes were  analyzed  using  the  Nutritionist  4 software  (First
atabank Inc.,  Hearst  Corp.  -  San  Bruno,  CA,  United  States).
ata entry  was  performed  by  a  trained  dietitian.  If  a  partic-
pant ate  a  food  not  included  in  the  database,  another  food
ith very  similar  nutrient  composition  was  selected.  Nutri-
nt information  was  also  obtained  through  food  labels  or
ecipes from  participants.  Participants  were  encouraged  to
eep their  dietary  intakes  and  exercise  patterns  monitored
y the  Physical  Activity  Questionnaire  for  Older  Children
PAQ-C) unchanged  during  the  experiment.tatistical  analysis
he  Statistical  Package  for  Social  Sciences  (SPSS)  version
6.0 for  Windows  (SPSS  -  Chicago,  IL,  United  States)  was
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Table  1  Anthropometric  measuresa of  participants  before  and  after  the  trial.
Variables  Stage  Synbiotic  group  Placebo  group  pb
n  29  27
Age  (years)  10.75  ±  2.49  10.09  ±  1.93  0.61
Weight  (kg)  Before  53.29  ±  3.52  46.84  ±  1.97  0.12
After  52.90  ±  3.43  48.84  ±  2.34  0.34
Difference  0.39  ±  0.25  -2.00  ±  1.23  0.06
pc <  0.0001 < 0.0001
Body  mass  index  Z-score Before  1.79  ±  0.50 1.6  ±  0.39 0.34
After  1.69  ±  0.51 1.65  ±  0.36 0.74
Difference  0.09  ±  0.07  0.02  ±  0.1  0.002
pc <  0.0001  0.38
Waist  circumference  (cm)  Before  84.22  ±  15.36  76.53  ±  9.92  0.32
After  82.89  ±  15.18  76.85  ±  9.82  0.08
Difference  -1.32  ±  0.66  0.31  ±  0.88  <  0.0001
pc <  0.0001  0.73
Waist-  to-  hipratio  Before  0.36  ±  0.09  0.41  ±  0.42  0.53
After  0.35  ±  0.09  0.34  ±  0.06  0.49
Difference  0.008  ±  0.009  0.073  ±  0.44  0.43
pc <  0.0001  0.40
a Values are presented as mean ± standard deviation.
b p-value resulted from Student’s t-test for independent variables for difference between probiotic and placebo groups after
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c p-value resulted from paired Student’s t-test for difference w
sed  for  statistical  analysis.  Descriptive  data  were  expressed
s mean  ±  standard  deviation  (SD).  After  assessment  of  the
ormal distribution  by  the  Kolmogorov-Smirnov  test,  intra-
roup changes  were  compared  by  the  paired  Student’s
-test, and  Student’s  t-test  for  independent  variables  was
sed for  inter-group  comparison.  Data  of  overweight  and
bese participants  were  also  compared.  Paired  Student’s
-test was  also  used  for  comparing  before-and-after  inter-
ention within  each  group.  Ptime,  Pgroup and  Ptime × group
ere  measured  for  each  variable  through  analysis  of  the
ovariance (ANCOVA).  Total  fecal  bacterial  counts  of  the  two
roups studied  were  compared  at  baseline,  and  on  the  day  15
nd 60  of  the  trial.  p-values  lower  than  0.05  were  considered
s statistically  signiﬁcant.
esults
verall,  56  out  of  70  participants  (80%)  completed  the  study;
he rest  did  not  have  complete  adherence.  The  participants
ho completed  the  trial  demonstrated  good  compliance
ith the  supplement  consumption,  and  no  adverse  effects
r symptoms  were  reported.
hysical  characteristics
he  demographics  and  physical  characteristics  at  the  begin-
ing of  the  study  did  not  differ  signiﬁcantly  between  the  two
roups. Table  1  presents  the  comparisons  of  anthropomet-
ic measures  between  the  synbiotic  and  placebo  groups,  as
ell as  intra-group  differences  before  and  after  the  trial.
he BMI  Z-score  decreased  signiﬁcantly  in  the  synbiotic
roup (1.79  ±  0.09  vs.  1.69  ±  0.09,  respectively,  p  <  0.0001),
hereas the  corresponding  ﬁgure  was  not  signiﬁcant  in  the
D
T
ﬁgroups throughout the study.
lacebo  group  (1.67  ±  0.07  vs.  1.65  ±  0.07,  respectively,  p
 0.38).  Likewise,  the  change  in  the  mean  waist  circumfer-
nce was  signiﬁcant  in  the  synbiotic  group  (84.22  ±  2.85  vs.
2.89 ±  2.82  cm,  respectively,  p  <  0.0001),  but  not  signiﬁ-
ant in  the  placebo  group  (76.53  ±  1.91  vs.  76.85  ±  1.92  cm,
espectively, p  =  0.73)
ietary  intake  and  physical  activity  level  of
articipants
he  energy  and  nutrient  intake,  as  well  as  the  levels  of  phys-
cal activity,  were  not  signiﬁcantly  different  between  the
wo groups,  and  did  not  change  signiﬁcantly  during  the  study
Table 2).
aboratory  ﬁndings
s  presented  in  Table  3,  during  the  experimental  period,
he fecal  total  counts  increased  signiﬁcantly  in  the  synbiotic
roup compared  to  the  placebo  group.9
The  mean  (SE)  of  inﬂammation  factors  before  and  after
eceiving synbiotic  supplement  and  placebo  are  presented  in
able 4.  Compared  with  the  placebo  group,  the  supplement
roup presented  a signiﬁcant  decrease  in  TNF-,  IL-6  lev-
ls, and  a  signiﬁcant  increase  in  adiponectin;  these  changes
ere no  longer  signiﬁcant  after  adjustment  for  BMI.  There
as no  signiﬁcant  change  in  high-sensitivity  C-reactive  pro-
ein (hs-CRP)  level.iscussion
o  the  best  of  the  authors’  knowledge,  this  trial  was  the
rst of  its  kind  in  the  pediatric  age  group  to  investigate  the
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Table  2  Dietary  intake  and  physical  activity  level  of  participants  throughout  the  trial.
Stage  Synbiotic  group  (n  =  29)  Placebo  group  (n  =  27)  p-value
Physical  activity
Before 2.31  ±  0.47  2.44  ±  0.50  0.30
After 2.41  ±  0.51  2.44  ±  0.57  0.83
Difference -0.10  ±  0.61  0.00  ±  0.67  0.55
pa 0.37  1.00
Energy  (kcal)
Before  1,508  ±  44.69 1,454  ±  44.69  0.35
After 1,516  ±  33.83 1,433  ±  35.06 0.09
Difference -7.90  ±  34.36 20.90  ±  28.61 0.52
pa 0.82  0.41
Protein  (g)
Before 59.40  ±  2.48  64.20  ±  2.93  0.21
After 55.22  ±  1.88  58.14  ±  1.96  0.28
Difference 8.87  ±  4.72  6.05  ±  3.50  0.66
pa 0.12  0.09
Carbohydrate  (g)
Before 187.05  ±  6.39 179.24  ±  6.91 0.41
After 189.68  ±  6.94 183.05  ±  7.31  0.51
Difference -2.63  ±  6.07 -3.80  ±  7.12 0.90
pa 0.66  0.59
Total  fat  (g)
Before 65.08  ±  4.54  58.05  ±  3.76  0.24
After 65.39  ±  8.83  61.62  ±  1.21  0.07
Difference -0.31  ±  5.06  -3.57  ±  3.55  0.60
pa 0.95  0.32
Saturated  fat  (g)
Before 17.93  ±  0.80  17.14  ±  0.74  0.47
After 18.61  ±  0.90  17.54  ±  0.71  0.37
Difference -0.66  ±  1.03  -0.43  ±  0.81  0.85
pa 0.51  0.59
Mono  unsaturated  fat  (g)
Before 16.92  ±  0.78 17.02  ±  0.87  0.93
After 17.97  ±  0.47 16.79  ±  0.59 0.12
Difference -1.05  ±  0.83  0.23  ±  0.84  0.28
pa 0.21  0.78
Poly  unsaturated  fat  (g)
Before 13.71  ±  0.69  13.15  ±  0.69  0.53
After 14.23  ±  0.45  13.49  ±  0.39  0.22
Difference -0.52  ±  0.49  -0.33  ±  0.33  0.79
pa 0.30  0.49
cholesterol  (g)
Before 257.44  ±  13.58  233.11  ±  8.12  0.13
After 257.26  ±  9.08  241.72  ±  10.52  0.26
Difference 0.17  ±  14.45  -8.60  ±  9.64  0.61
pa 0.99  0.38
Dietary  ﬁber  (g)
Before 12.21  ±  0.84  14.00  ±  0.72  0.11
After 11.14  ±  0.70  12.37  ±  0.51  0.16
Difference 1.07  ±  0.79  1.62  ±  0.96  0.66
pa 0.18  0.10
Data are presented as means ± standard error (SE) for nutrient.
Data are presented as means ±standard deviation for physical activity.
pa, p-value resulted from paired Student’s t-test for difference within groups throughout the study.
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Table  3  Bacterial  count  in  stool  at  three  times  during  the  trial.
Type  of  Bacteria  Stage  Synbiotic  group  Mean  ±  SD  Placebo  group  Mean  ±  SD
Genus  Lactobacillus  Baseline  46990603  ±  68305170  35554312  ±  52377526
Day 15  9.8849404  ±  56632828  20521047  ±  14446100
Day 60  104007006  ±  95400927  28320225  ±  28512981
p-value  0.029  0.69
Biﬁdobacteria Baseline  483104.1  ±  1083977.2  1856453.3  ±  5486345.3
Day 15 92521.0 ±  117058.9 35964.9  ±  26621.0
Day 60 1965978.9 ±  2699014.4 337154.7  ±  610843.9
p-value  0.06  0.39
e
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tSD, standard deviation.
ffect  of  synbiotic  supplementation  on  inﬂammatory  fac-
ors in  overweight  and  obese  children  and  adolescents.  It
as observed  that  the  intake  of  synbiotic  had  favorable
esults in  weight  reduction  of  obese  children  and  adoles-
ents, as  well  as  in  signiﬁcant  changes  of  serum  TNF,  IL-6,
nd adiponectin,  without  change  in  the  hs-CRP  level.  How-
ver, the  changes  in  inﬂammation  markers  were  dependent
n weight  reduction.During  the  study  period,  the  energy,  macronutrient,  and
lso antioxidant  intake,  and  the  level  of  physical  activi-
ies did  signiﬁcantly  change  within  each  group,  besides  an
ncrease in  concentrations  of  protective  bacteria,  as  shown
t
d
t
t
Table  4  Effects  of  synbiotic  and  placebo  consumption  on  inﬂamm
Variables  Stage  Synbiotic  group
n =  28
mean  ±  SE
Placebo  grou
n =  27
mean  ±  SE
Hs-CRP  Before  2.05  ±  0.92  1.66  ±  0.96  
After  1.03  ±  0.14  1.75  ±  0.13  
Difference -0.7  ±0.07  0.09  ±  0.05  
pe 0.02  0.75
TNF Before  123.14  ±  9.63  94.15  ±  9.44  
After  113.25  ±  3.30  103.40  ±  3.26
Difference -9.89  ±  0.55  9.25  ±  0.68  
pe 0.02  0.10
Adjustedf 1.02  ±  0.08  1.14  ±  0.09  
IL-6 Before  130.07  ±  4.73  121.30  ±  4.50
After  119.25  ±  3.62  120.33  ±  4.66
Difference -10.82  ±  0.64  -0.96  ±  0.82  
pe 0.04  0.76
Adjustedf 1.13  ±  0.05  1.26  ±  0.06  
Adiponectin Before  261.61  ±  3.96  283.67  ±  3.17
After  289.64  ±  11.59  279.07  ±  11.8
Difference 28.03  ±  1.39  -3.69  ±  1.97  
pe P  <  0.0001  0.79
Adjustedf 2.94  ±  0.90  2.74  ±  0.14  
Hs-CRP, high sensitivity C-reactive protein; IL-6, Interleukin 6; TNF, t
All values are expressed as mean ± standard error (SE).
a p-values present the comparison of baseline (computed by Student
two groups (computed by analysis of the covariance [ANCOVA]).
b p-values represent the time x group interaction (computed by ANCO
c p-values demonstrate the effect of time (computed by ANCOVA).
d p-values represent the effect of grouping (computed by ANCOVA).
e p-values present comparison of baseline and end point values withi
f Adjusted for weight.y  the  microbiological  data,  and  their  metabolic  activities
uggest that  the  obtained  results  may  be  due  to  the  synbiotic
upplementation.
Cani et  al.  recently  demonstrated  that  mice  fed  a  high-fat
iet were  characterized  by  an  increase  in  gut  permeabil-
ty and  metabolic  endotoxaemia  or  LPS,10 which  consists
n leakage  into  the  body  from  the  Gram-negative  part  of
he intestinal  microbiota,  and  its  factors  are  involved  in
he onset  and  progression  of  inﬂammation  and  metabolic
iseases.4 Thus,  probiotics  may  be  effective  in  improving
he gut-barrier  and  suppressing  Gram-negative  bacteria  in
he gastrointestinal  channel.13,14 It  was  demonstrated  that
ation  markers.
p pa Time  ×  groupb Timec Groupd
0.42  0.61  0.141  0.92
0.17
0.06
0.06  0.008  0.92  0.152
 0.48
p  <  0.0001
0.105
 0.37  0.118  0.06  0.72
 0.92
P<0.0001
0.06
 0.34  0.05  0.139  0.82
3  0.70
p  <  0.0001
0.25
umor necrosis factor .
’s t-test for independent samples) and end-point values between
VA).
n each group (computed by paired Student’s t-test).
CT
A
T
T
I
R
1
1
1
1
1
1Synbiotic  and  inﬂammation  in  childhood  obesity  
probiotics  strains  such  as  Lactobacillus  rhamnosus  GG  and
Lactobacillus casei  DN-114--001  protect  the  epithelial  bar-
rier function  against  Escherichia  coli-induced  redistribution
of the  tight-junction  proteins,15,16 and  that  some  probiotic
strains, such  as  L.  plantarum  299  v,  can  mitigate  bacterial
translocation.17,18
High-fat  diet  contributes  to  the  disruption  of  the  tight-
junction proteins  (zonula  occludens-1 Z◦−1 and  occludin)
involved in  the  gut  barrier  function,10,19 and  modulation  of
gut microbiota  of  mice  with  prebiotic  would  lead  to  lower
levels of  several  plasma  cytokines,  such  as  TNF-  and  IL-
6, due  to  promotion  of  tight-junction  proteins  (ZO-1  and
occludin) disruption.  These  data  conﬁrm  that  obese  mice
exhibit an  altered  gut  barrier,  characterized  by  a  disruption
of tight-junction  proteins.  Cani  et  al.  concluded  that  the
modulation of  the  gut  microbiota  using  prebiotics  in  obese
mice could  act  favorably  on  the  intestinal  barrier,  thereby
reducing endotoxaemia  and  systemic  and  liver  inﬂamma-
tion, with  beneﬁcial  consequences  on  associated  metabolic
disorders.19,20
Furthermore,  it  has  been  demonstrated  in  healthy
humans that  L.  plantarum  WCSF1  increased  the  relocation
of occludin  and  ZO-1  into  the  tight  junction  area  between
duodenal epithelial  cells.21
The  presents  ﬁndings  are  consistent  with  those  on  the
connection between  gut  microbiota,  inﬂammation,  and
homeostasis, and  their  role  in  the  pathogenesis  of  obesity
and related  disorders,19,22 as  well  as  with  the  ﬁndings  on
the relationship  of  diet  and  gut  microbiota  with  homeosta-
sis, as  investigated  in  experimental  models  of  diet-induced
obesity.23,24 It  appears  that,  because  of  the  association
between obesity  and  inﬂammation,25 it  can  be  proposed
that the  favorable  effects  of  probiotics  in  controlling
inﬂammation may  play  a  role  in  obesity  prevention  and
control.
Among the  probable  mechanisms,  it  has  been  demon-
strated that  the  modulation  of  the  gut  microbiota  increases
villus height  and  crypt  depth,  and  leads  to  a  thicker
mucosal layer  in  the  jejunum  and  in  the  colon.26
These  effects  are  due  to  fermentation  products  of  bac-
teria, mainly  short-chain  fatty  acids  (SCFAs),  such  as
butyrate, which  acts  as  an  energetic  substrate  for  the
colonocytes and  have  a  trophic  effect  on  mucosa.27,28
In  the  present  study,  this  mechanism  was  highlighted,
because an  increase  in  the  concentrations  of  protective
bacteria due  to  the  synbiotic  supplementation  was  docu-
mented.
Plasma adipocytokine  levels  rise  with  an  increase  in
adipose tissue  and  adipocyte  volume,  except  for  plasma
adiponectin, which  is  lower  in  obesity.29,30 In  the  present
study, the  increase  in  plasma  adiponectin  was  due  to  weight
reduction and  suppression  of  fat  tissue.
In  conclusion,  the  present  ﬁndings  suggest  the  positive
inﬂuence of  synbiotic  supplementation  on  inﬂammation  fac-
tors, whose  changes  are  dependent  on  weight  reduction  in
overweight and  obese  children.Funding
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